slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 3,601-3,630
Pages 350
Rows per page 30
Slide type
3,601-3,630 of 10,471
11
The slide uses a 'before-after' style comparison between national benchmarks and Cano Health performance.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The chart shows a clear downward trend in expense ratios from 73% for new members (<6 months) to 40% for long-term members (>36 months).Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
Cano Health | Investor Presentation Deck | 45 slidesCano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Data reflects pro forma figures for acquisitions as of 3/31/2021.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
22
The charts use a stacked bar format to distinguish between base Cano Health performance and PF Acquisitions.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations Beat · Financials1 hit
37
The chart compares medical claims expense ratios for members with <24 months vs >24 months tenure, showing a consistent improvement (lower ratio) for longer-tenured members.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
38
The chart demonstrates that while expense ratios increase with the number of chronic conditions, they remain within a specific range for the company's model.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
40
The chart highlights the shift to telehealth during the peak of the pandemic while maintaining total visit volume.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
41
The data compares Cano Health patients to the general population in Florida counties where Cano operates, specifically for patients aged 65+.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
43
Includes a timeline of market entry and expansion activities.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
15
The charts show that chRDNA guides maintain high on-target editing while significantly reducing off-target editing compared to all-RNA guides.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · TractionLoop · Zoom In1 hit
22
Includes bioluminescence imaging time-series and Kaplan-Meier survival curve.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
23
Kaplan-Meier survival plots are standard for preclinical efficacy demonstration.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
31
Kaplan-Meier survival curves showing superior efficacy of CB-011.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
35
The chart is a Kaplan-Meier survival plot. The p-value < 0.0001 indicates statistical significance.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
39
The slide presents four distinct assays validating the functional equivalence of iNK cells to primary NK cells.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank 1 hit
42
The slide uses a split-column layout to contrast past performance with future roadmap items.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank 1 hit
19
Data shows efficacy of ERAS-007 in combination with Encorafenib and Cetuximab in BRAF-mutant colorectal cancer models.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
20
The slide demonstrates efficacy in two distinct models (HCC827/ER1 and NCI-H820).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
21
The slide presents preclinical efficacy data for ERAS-007 in two different KRAS-mutant cancer models.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
22
The chart displays individual patient responses (waterfall plot) categorized by dose level.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
23
The chart uses color to represent dosage and symbols to represent clinical response (Partial Response, Stable Disease, Progressive Disease).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
24
Includes patient history details (genetics, prior treatments, dosage) for two case studies.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
33
TGI = Tumor Growth Inhibition. Data shows mean tumor volume over time.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
34
NSCLC EGFR exon 19 deletion CDX model HCC827Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
35
CRC KRAS G12C PDX CO-04-0310 model used for efficacy and safety assessment.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
37
The chart shows Day 1 and Day 15 profiles with a reference line for pERK H358 IC50/fu.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
09
OOH stands for Out-of-Home.European Wax Center | IPO Presentation Deck | 34 slides · European Wax Center
Pitch deck Investment bank Beat · Problem1 hit
14
The chart demonstrates the maturity curve of different franchise cohorts, showing that they consistently reach ~$1.0MM in revenue by year 5.European Wax Center | IPO Presentation Deck | 34 slides · European Wax Center
Pitch deck Investment bank 1 hit
15
The chart highlights the impact of the 2020 pandemic and the subsequent recovery, supporting the claim of non-discretionary demand.European Wax Center | IPO Presentation Deck | 34 slides · European Wax Center
Pitch deck Investment bank 1 hit